Analytical Data
-
基因名
GP1BB
- Application
-
别名
GP1BB；Platelet glycoProtein Ib beta chain
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P13224-1
-
表达区间
1-147aa
-
氨基酸序列
MGSGPRGALS LLLLLLAPPS RPAAGCPAPC SCAGTLVDCG RRGLTWASLP TAFPVDTTEL VLTGNNLTAL PPGLLDALPA LRTAHLGANP WRCDCRLVPL RAWLAGRPER APYRDLRCVA PPALRGRLLP YLAEDELRAA CAPGPLC
-
分子量
14 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GP1BB is a crucial component in the study of platelet biology and thrombosis. It is a part of the glycoprotein (GP) receptor complex on the platelet surface, specifically associated with GP1b, which plays a vital role in mediating interactions between platelets and the vascular endothelium. Research into GP1BB is primarily driven by its implications in various pathological conditions, including bleeding disorders and thrombotic diseases. Mutations or deficiencies in GP1BB can lead to Bernard-Soulier syndrome, a genetic condition characterized by prolonged bleeding due to impaired platelet function. Understanding the structure-function relationship of GP1BB can provide insights into the mechanisms underlying platelet activation and aggregation, essential processes in hemostasis. Furthermore, GP1BB serves as a potential therapeutic target for the development of new anticoagulant therapies, aimed at mitigating thrombotic events in cardiovascular diseases. Advances in recombinant protein technologies have paved the way for the production and characterization of GP1BB, enabling detailed studies of its biochemical properties and interactions. Ultimately, this research holds promise not only for elucidating the fundamental biology of platelets but also for translating findings into clinical approaches that enhance patient outcomes in disorders related to abnormal platelet function.
